Autoimmunity specialist AbolerIS Pharma will use a €27.3m Series A Financing to advance its first-in-class antibody inducing immune tolerance in rheumatoid arthritis into the clinic.
https://european-biotechnology.com/wp-content/uploads/2024/04/AborelS_Pharma.png12982048Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2023-09-19 07:14:002024-07-09 14:13:38Aboleris Pharma bags €27.3m in Series A Financing